SG11202103796TA - Indole ahr inhibitors and uses thereof - Google Patents
Indole ahr inhibitors and uses thereofInfo
- Publication number
- SG11202103796TA SG11202103796TA SG11202103796TA SG11202103796TA SG11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA
- Authority
- SG
- Singapore
- Prior art keywords
- ahr inhibitors
- indole
- indole ahr
- inhibitors
- ahr
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746277P | 2018-10-16 | 2018-10-16 | |
| PCT/US2019/056455 WO2020081636A1 (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103796TA true SG11202103796TA (en) | 2021-05-28 |
Family
ID=70284697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103796TA SG11202103796TA (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220144839A1 (en) |
| EP (1) | EP3867253A4 (en) |
| JP (1) | JP2022502476A (en) |
| KR (1) | KR20210110566A (en) |
| CN (1) | CN113272305A (en) |
| AU (1) | AU2019360204A1 (en) |
| BR (1) | BR112021007017A2 (en) |
| CA (1) | CA3115711A1 (en) |
| EA (1) | EA202190726A1 (en) |
| IL (1) | IL282252A (en) |
| MX (1) | MX2021004245A (en) |
| SG (1) | SG11202103796TA (en) |
| WO (1) | WO2020081636A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201909710XA (en) | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| ES3028099T3 (en) | 2019-11-26 | 2025-06-18 | Ikena Oncology Inc | Polymorphic carbazole derivatives and uses thereof |
| KR20220125323A (en) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | AHR inhibitors and uses thereof |
| JP2023530664A (en) * | 2020-06-10 | 2023-07-19 | デリックス セラピューティクス，インク． | Tricyclic psychoplastogens and their uses |
| CN114369097B (en) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | Heteroaromatic AhR inhibitors |
| EP4236960A1 (en) * | 2020-10-28 | 2023-09-06 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN114456178B (en) * | 2021-01-13 | 2023-06-02 | 北京华森英诺生物科技有限公司 | Application of tetrahydropyrimidine [1,2-b ] indazole-4-amine derivatives as AhR inhibitor and preparation method thereof |
| CN114805361B (en) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN117624168A (en) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | Fused ring heterocyclic compounds and their preparation methods and applications |
| EP4617262A1 (en) | 2022-11-07 | 2025-09-17 | Kyoto University | Nitrogen-containing heterocyclic compound |
| KR20240169284A (en) | 2023-05-24 | 2024-12-03 | 경희대학교 산학협력단 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, IMPROVING OR TREATING AhR-MEDIATED DISEASE |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) * | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| AU2004230928B2 (en) * | 2003-04-09 | 2010-12-02 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| AR047969A1 (en) * | 2004-02-25 | 2006-03-15 | Schering Corp | PIRAZOLOTRIAZINAS AS QUINASA INHIBITORS |
| PE20100362A1 (en) * | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| WO2017004405A1 (en) * | 2015-07-01 | 2017-01-05 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
| US20180072741A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| SG11201909710XA (en) * | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
-
2019
- 2019-10-16 SG SG11202103796TA patent/SG11202103796TA/en unknown
- 2019-10-16 EA EA202190726A patent/EA202190726A1/en unknown
- 2019-10-16 JP JP2021521024A patent/JP2022502476A/en active Pending
- 2019-10-16 US US17/281,395 patent/US20220144839A1/en not_active Abandoned
- 2019-10-16 CA CA3115711A patent/CA3115711A1/en active Pending
- 2019-10-16 AU AU2019360204A patent/AU2019360204A1/en not_active Abandoned
- 2019-10-16 CN CN201980076086.7A patent/CN113272305A/en active Pending
- 2019-10-16 BR BR112021007017-6A patent/BR112021007017A2/en unknown
- 2019-10-16 KR KR1020217014753A patent/KR20210110566A/en not_active Withdrawn
- 2019-10-16 MX MX2021004245A patent/MX2021004245A/en unknown
- 2019-10-16 EP EP19873025.1A patent/EP3867253A4/en not_active Withdrawn
- 2019-10-16 WO PCT/US2019/056455 patent/WO2020081636A1/en not_active Ceased
-
2021
- 2021-04-12 IL IL282252A patent/IL282252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL282252A (en) | 2021-05-31 |
| EP3867253A4 (en) | 2022-05-18 |
| AU2019360204A1 (en) | 2021-06-03 |
| BR112021007017A2 (en) | 2021-07-13 |
| MX2021004245A (en) | 2021-09-08 |
| EA202190726A1 (en) | 2021-08-19 |
| US20220144839A1 (en) | 2022-05-12 |
| WO2020081636A1 (en) | 2020-04-23 |
| JP2022502476A (en) | 2022-01-11 |
| EP3867253A1 (en) | 2021-08-25 |
| CN113272305A (en) | 2021-08-17 |
| KR20210110566A (en) | 2021-09-08 |
| CA3115711A1 (en) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282252A (en) | Indole ahr inhibitors and uses thereof | |
| SG11202104017VA (en) | Tyk2 inhibitors and uses thereof | |
| IL283639A (en) | Kif18a inhibitors | |
| IL272649B (en) | Ahr inhibitors and uses thereof | |
| IL271999A (en) | Tyk2 inhibitors and uses thereof | |
| IL276147A (en) | Gcn2 inhibitors and uses thereof | |
| IL276095B1 (en) | Gcn2 inhibitors and uses thereof | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| IL283409A (en) | Tyk2 inhibitors and uses thereof | |
| IL268619B (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
| IL280051A (en) | Ep4 inhibitors and synthesis thereof | |
| PL3621694T3 (en) | Lrrc33 inhibitors and use thereof | |
| SG11202102379XA (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| IL280408A (en) | Cdk inhibitors and uses thereof | |
| HK40058976A (en) | Indole ahr inhibitors and uses thereof | |
| HK40023946A (en) | Indole ahr inhibitors and uses thereof | |
| HK40026667A (en) | Ahr inhibitors and uses thereof | |
| HK40078624A (en) | Ahr inhibitors and uses thereof | |
| GB201908884D0 (en) | Inhibitors and use | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |